Morbid obesity has been associated with a number of gastrointestinal diseases. It has been shown to be an important risk factor in the development of gastroesophageal reflux disease (GERD), erosive esophagitis, and hiatal hernia [1]. Upper digestive diseases are 2–3 times more common in obese than in normal weight individuals, including erosive esophagitis, gastroesophageal reflux, hiatal hernia, Barrett’s esophagus, and *H. pylori* infection [2].

The possible benefits of using preoperative upper endoscopy as a tool in the assessment of obese patients before bariatric surgery have not yet been determined. Some physicians consider it mandatory to rule out any upper gastrointestinal disease that may affect surgery because it would be difficult to assess all parts of the gastrointestinal tract after some bariatric procedures; however, others still believe that endoscopy is unnecessary and may expose patients to an unnecessary procedure, sedation, and possible complications, especially since most obese patients have multiple comorbidities.
Many authors suggest performing esophagogastroduodenoscopy (EGD) in all patients before bariatric procedures because of the lack of correlation between patient symptoms and EGD findings [3]. On the other hand, many other investigators advocate a selective approach for asymptomatic patients because of the relatively weak clinical relevance of the majority of lesions discovered on routine EGD along with the cost and invasiveness of EGD [3].

**Patients and methods**

All patients presenting to our department requesting weight reduction surgery were reviewed by our bariatric team. Bariatric surgery was offered to patients who fulfilled the criteria of our hospital bariatric unit protocol and were selected by the bariatric team as candidates for surgery (patients with body mass index (BMI) > 35 kg/m² with known comorbidities, or patients with BMI > 40 kg/m² without known comorbidities). The type of procedure was discussed and agreed between the patient and the bariatric team after reviewing all investigations.

Gastroscopy is routinely performed in our hospital before any bariatric procedure in order to assess the upper gastrointestinal tract for any abnormal findings. Gastroscopy was performed by experienced endoscopists in our gastroenterology department under local spray anesthesia with or without sedation and the findings were recorded in a hospital database system. The Campylobacter-like organism test (CLO test) to detect *H. pylori* was carried out in all endoscopic procedures and, in the presence of any ulcer or lesion, multiple biopsies were taken.

We retrospectively reviewed the medical records of all patients admitted for bariatric surgery in our center between January 2013 and June 2016. The study included only asymptomatic patients. Patients who were symptomatic, those taking NSAIDs or steroids, and those with a previous history of gastric diseases were not included. In total, 1473 files were reviewed; however, gastroscopy results were not available in 195 files (gastroscopy done in other institutes) and these files were excluded from the study; the remaining 1278 patients were included in data collection.

Data collected included age, sex, preoperative BMI, all gastroscopy findings, duration of endoscopy, and any associated complications.

Patients were divided into three groups according to the gastroscopy findings: Group 0 included patients with normal endoscopy; Group 1 included patients with endoscopic findings that were not significant and did not interfere with the procedure plan; Group 2 included patients with significant findings that affected the procedure in some way (procedure postponed or cancelled, or the type of procedure was changed). In the presence of multiple findings on gastroscopy, the most serious abnormality with the most significant impact on the bariatric procedure was considered for counting and data analysis.

**Results**

Between January 2013 and June 2016, 1473 patients were admitted to our unit for bariatric surgery, and data from the 1278 files available were collected and analyzed. The mean age of the patients was 41.3 ± 12.7 years, 61% were female and 39% were male, and the mean BMI was 43.7 ± 8 kg/m².

Endoscopic findings were variable among different patients.

<table>
<thead>
<tr>
<th>Group</th>
<th>Classification of findings</th>
<th>Findings</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 0</td>
<td>No findings</td>
<td>Normal endoscopy</td>
<td>135</td>
</tr>
<tr>
<td>Group 1</td>
<td>Non-significant findings</td>
<td>Simple gastritis</td>
<td>419</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simple duodenitis</td>
<td>127</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Positive CLO test with no other significant findings</td>
<td>364</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small hiatal hernia &lt; 2 cm</td>
<td>115</td>
</tr>
<tr>
<td>Group 2</td>
<td>Significant findings</td>
<td>Esophagitis/GERD</td>
<td>259</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Barrett’s esophagus</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Large hiatal hernia &gt; 2 cm</td>
<td>189</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Erosive gastritis/duodenitis</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Positive CLO test with other significant findings</td>
<td>215</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peptic ulcer</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mass lesion/cancer</td>
<td>4</td>
</tr>
</tbody>
</table>

CLO, Campylobacter-like organism; GERD, gastroesophageal reflux disease.

| Table 1 Endoscopic findings among patients in the study. |
419/1278 patients (32.8%) while simple duodenitis was found in 127/1278 patients (9.9%), and a small hiatal hernia (<2 cm) was present in 115/1278 patients (9.0%). On the other hand, significant findings were more common and included: esophagitis and GERD in 259/1278 patients (20.3%), Barrett’s esophagus in 38/1278 patients (3.0%), large hiatal hernia (>2 cm) in 189/1278 patients (14.8%), erosive gastritis (gastric mucosal damage or erosions that could bleed easily) and duodenitis in 241/1278 patients (18.9%), positive CLO test in 579/1278 patients (45.3%), peptic ulcer in 85/1278 patients (6.7%), and a mass lesion or cancer in 4/1278 patients (0.3%). A positive CLO test was associated with other significant findings in 215 patients, while 364 patients had a positive CLO test with no other associated significant findings.

Patients with normal endoscopy proceeded directly to bariatric surgery. Patients with simple gastritis and duodenitis were started on oral proton pump inhibitors and diet modification and then proceeded to surgery. Patients with small hiatal hernias proceeded directly to surgery if there were no symptoms, and the hernia was assessed intraoperatively. Patients with severe esophagitis, GERD, Barrett’s esophagus or large hiatal hernias were started on diet modification and proton pump inhibitors but these conditions were considered to be an indication for gastric bypass and a contraindication for sleeve gastrectomy. In this study, we did not consider the grading of GERD as an indicator for diversion surgery; however, we considered GERD to be severe and a contraindication for sleeve gastrectomy once it was associated with esophagitis and/or Barrett’s esophagus.

For patients with a positive CLO test and no other significant findings, bariatric surgery was postponed (for approximately 6 weeks) until they had received a full course of treatment (triple therapy as advised by the gastroenterology team), but these patients were not counted in the significant group because many authors [4, 5] do not consider a positive CLO test alone to be a significant finding before bariatric surgery; these patients had a urea breath test to ensure eradication of H. pylori after completion of treatment in addition to clinical assessment and then surgery was performed. The procedures for patients with a positive CLO test and other significant findings such as erosive gastritis/duodenitis or peptic ulcers (duodenal/gastric) were postponed until the patients had received full treatment. If repeat upper endoscopy and CLO test after 8–10 weeks showed resolution of erosions or healed ulcers and eradication of H. pylori, they then proceeded to surgery.

All patients were kept on daily proton pump inhibitors for 3–6 months after bariatric surgery. The procedure was completely cancelled for four patients in whom mass lesions/cancer was detected and they were treated accordingly; one patient had a lower esophageal cancer, one patient had gastric adenocarcinoma and two patients had gastrointestinal stromal tumors (GIST). No complications were reported during or after endoscopy among all patients in this series.
The patients were assigned to the groups as previously discussed: Group 0 with normal endoscopy included 10.6% of patients (n = 135), Group 1 with non-significant findings alone that did not affect the timing or type of planned surgery included 25.6% of patients (n = 327), while the majority of patients (63.8%, n = 816) were assigned to Group 2 with significant findings that necessitated delaying the procedure (for approximately 10±2 weeks), changing the type of procedure or even canceling it (Fig. 2).

Since 2013, the bariatric surgical protocol at our hospital has followed this classification. For all patients in Group 2, bariatric surgery was postponed and they were operated later after finishing their treatment. For those patients who needed to change the type of procedure, the reason was explained to them and they agreed on the change. For those patients who had pathologies necessitating canceling the procedure, they were referred to the appropriate facility to continue work-up and treatment of the new pathology detected.

Discussion

The implementation of routine upper endoscopy in the preoperative preparation of all obese patients presenting for bariatric surgery remains one of the most controversial topics among surgeons and different bariatric units. Patients who are planned for restrictive procedures such as a sleeve gastrectomy or an adjustable gastric banding may be at greater risk of worsening of gastroesophageal reflux, Barrett’s esophagus, and other complications [6,7]. These patients will need better counseling and the selection of a more appropriate bariatric procedure. Moreover, bypass procedures such as Roux-en-Y gastric bypass will result in an inaccessible foregut which will make future evaluation of the upper gastrointestinal tract problematic, especially if these patients have an increased risk or pre-existing gastroduodenal pathology [8]. On the other hand, many other investigators advocate a selective approach for asymptomatic patients because of the relatively weak clinical relevance of the majority of lesions discovered on routine EGD along with the cost and invasiveness of the EGD [9,10]. Despite the presence of other modalities for evaluating the gastrointestinal tract such as barium meal, upper endoscopy remains by far the procedure of choice.

Guidelines pertaining to preoperative endoscopic screening are uncertain. The American Society for Gastrointestinal Endoscopy [11] does not recommend blanket screening but suggests the decision should be individualized to the patient. The European Association for Endoscopic Surgery [12], however, recommends preoperative endoscopy but provides scarce supporting evidence. To date, the American Society for Metabolic and Bariatric Surgery recommends endoscopic evaluation if clinically indicated [13], but there are no recommendations from the International Federation for the Surgery of Obesity, or any Asian consensus on this topic.

The prevalence of abnormal EGD findings in morbidly obese patients ranged from 30% to 89.7% [1]. The most commonly reported abnormalities were gastritis (13.6–28.7%), hiatal hernias (9–40%), and esophagitis (9.2–17%). A great variation is also noted in the prevalence of clinically significant EGD abnormalities, with rates ranging from 9.4% to 61.5%. Lee et al. demonstrated an overall prevalence of abnormal EGD of 51.1%, with 27.2% classified as clinically significant [1].

Frigg et al. advocated routine gastroscopy before bariatric surgery because of the high prevalence of upper gastrointestinal lesions [14]. Sharaf and colleagues further documented clinically important findings in 61.5% of patients having routine preoperative gastroscopy [15]. In a large series of 626 patients reported by Muñoz and colleagues [16], abnormalities were found in 46% of patients including early gastric cancer. On the other hand, other studies found that significant abnormalities affecting the procedure were not common. Schigt et al. [17] and Loewen et al. [9] found that gastroscopic findings only delayed or changed surgical management in 1.3% and <1% of cases respectively. A large systematic review and meta-analysis by Bennett and colleagues [18] concluded that preoperative endoscopy in average risk, asymptomatic bariatric surgery patients should be considered optional, as the proportion of endoscopies that resulted in important changes in management was low.

An explanation for the extremely variable results of significant findings among different studies is that different surgeons deal with endoscopic findings in different levels of significance with no clear definition of which findings are clinically significant and directly affect the planned surgery. This has led to different protocols in the management of gastroscopic findings [19,20]. Some surgeons believe that conditions such as hiatal hernia and gastroesophageal reflux are natural consequences of obesity and they will disappear naturally with weight reduction after a successful bariatric surgery. Others believe that these conditions are vital aspects of obesity management, which have significant implications for the selection of subsequent surgical procedures. In their study, Ng et al. [21] considered erosive gastritis or esophagitis, benign or malignant tumors and ulcer disease to be clinically significant and they correlated hiatal hernia with symptoms and explored it intraoperatively to decide about crural repair. They found that crural repair was deemed to be sufficient and none of the patients had...
a modification of surgery to a gastric bypass. In our unit, large symptomatic hiatal hernias are repaired; esophagitis and Barrett’s esophagus are considered to be a contraindication for sleeve gastrectomy; erosive gastritis, duodenitis and peptic ulcers are treated before proceeding to surgery. Cancer and GIST were detected in four patients and were considered to be an absolute contraindication for bariatric surgery and these patients were treated accordingly to their findings.

We compared our results with other previous studies (Table 2); there are some common results, especially those with significant abnormalities detected, although some other studies did not show similar findings. To our knowledge, and after a thorough review of Pubmed, Medscape, and Elsevier, our study represents the largest single-center study reviewing upper endoscopy results before bariatric surgery published in the English language literature. These significant numbers suggest that preoperative upper endoscopy is indicated and may need to be implemented in all bariatric centers.

**Conclusion**

Despite the fact that some surgeons are still reluctant to perform routine upper endoscopy before bariatric procedures; we found high clinical significance in doing so. The procedure was canceled, changed or postponed in 63.8% of patients due to significant abnormal findings in gastroscopy. There were no complications (morbidity or mortality) in the 1278 patients reviewed. The authors suggest that further studies with prospective follow-up could help to build more solid evidence and consequently help to implement upper endoscopy routinely before bariatric surgery.

**Competing interests**

None

---

**Table 2** Comparison of our results with results of previous similar studies.

<table>
<thead>
<tr>
<th>Reference, year</th>
<th>Number of patients</th>
<th>Mean age (years)</th>
<th>Mean BMI (kg/m²)</th>
<th>% Normal endoscopy</th>
<th>% Abnormal endoscopy</th>
<th>% Significant abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharaf et al. [15], 2004</td>
<td>195</td>
<td>41.2</td>
<td>48.9</td>
<td>10.3</td>
<td>89.7</td>
<td>61.5</td>
</tr>
<tr>
<td>Zeni et al. [22], 2006</td>
<td>159</td>
<td>41.1</td>
<td>49.7</td>
<td>33.4</td>
<td>66.6</td>
<td>9.4</td>
</tr>
<tr>
<td>Muñoz et al. [16], 2008</td>
<td>626</td>
<td>38.5</td>
<td>42</td>
<td>54</td>
<td>46</td>
<td>–</td>
</tr>
<tr>
<td>Loewen et al. [9], 2008</td>
<td>447</td>
<td>40.6</td>
<td>48.6</td>
<td>70</td>
<td>30</td>
<td>18</td>
</tr>
<tr>
<td>Schigt et al. [17], 2014</td>
<td>523</td>
<td>44.3</td>
<td>46.6</td>
<td>49.9</td>
<td>50.1</td>
<td>14.7</td>
</tr>
<tr>
<td>Lee et al. [1], 2017</td>
<td>268</td>
<td>39.1</td>
<td>40.3</td>
<td>48.9</td>
<td>51.1</td>
<td>27.2</td>
</tr>
<tr>
<td>This study</td>
<td>1473</td>
<td>41.3</td>
<td>43.7</td>
<td>10.6</td>
<td>89.4</td>
<td>63.8</td>
</tr>
</tbody>
</table>

BMI, body mass index.

**References**


